Results 241 to 250 of about 326,396 (335)

Immune-Related Peripheral Keratopathy in Post-COVID-19 Syndrome. [PDF]

Int Med Case Rep J
Chen B, Li X, Qu L, Wu S.
europepmc   +1 more source

Psilocybin in alcohol use disorder and comorbid depressive symptoms: Results from a feasibility randomized clinical trial

Addiction, EarlyView.
Abstract Background and Aims Psilocybin has emerged as a potential treatment for alcohol use disorder (AUD), but early efficacy data are inconsistent. Depression following alcohol detoxification significantly increases the risk of relapse. This pilot study aimed to evaluate the feasibility, acceptability, and preliminary efficacy of psilocybin‐assisted
Amandine Luquiens, Dahbia Belahda, Carine Graux, Noe Igounenc, Chris Serrand, Paul Rochefort, Thibault Mura, Felix Sergent   +7 more
wiley   +1 more source

The Impact of Metabolic Syndrome on the Outcomes of Rehabilitation in Post-COVID-19 Patients [PDF]

Alicja Mińko, Agnieszka Turoń-Skrzypińska, Aleksandra Rył, Iwona Rotter   +3 more
openalex   +1 more source

Post-COVID-19 syndrome and health-related quality of life after hospital discharge. [PDF]

Rev Saude Publica
Rocha RPS, Andrade ACS, Muraro AP.
europepmc   +1 more source

Long‐Term Efficacy and Safety of Ligelizumab as Re‐Treatment in Patients With Chronic Spontaneous Urticaria

Allergy, EarlyView.
Ligelizumab re‐treatment in CSU patients showed sustained efficacy and tolerability. Over 50% achieved symptom control (UAS7 ≤ 6) by Week 12; benefits maintained through Week 52. No new safety signals observed; aligns with prior PEARL trial outcomes. CSU, chronic spontaneous urticaria; mg, milligram; q4w, every 4 weeks; UAS, urticaria activity score ...
Ana M. Gimenez‐Arnau, Marcus Maurer, Adam Reich, Chia‐Yu Chu, Diana Deleanu, Gordon Sussman, Jorge Sanchez, Knut Brockow, Koremasa Hayama, Michihiro Hide, Mohamed Denguezli, Raisa Meshkova, Roberta F. J. Criado, Sarbjit Saini, Solange Valle, Eva Hua, Pengpeng Wang, Alis Burciu, Isabelle Indermuehle, Vineeth Varanasi, Yolandi Joubert, Thomas Severin, Manmath Patekar   +22 more
wiley   +1 more source

Rationale for the use of a fifth-generation multisymbiotic in medical rehabilitation of patients with post-acute COVID-19 syndrome

И. Н. Смирнова, Natalia M. Yurieva, Т Н Зарипова, И. И. Антипова, E V Titskaya, Alexey A. Zaytsev, Oleg V. Sorokin, Alexey V. Molokeev   +7 more
openalex   +2 more sources

Prevalence and characters of post-acute COVID-19 syndrome in healthcare workers in Kashan/Iran 2023: a cross-sectional study [PDF]

Hamidreza Zeraatkhah, Negin Masoudi Alavi, Hanieh Ziabakhsh, Zahra Mahdaviasl   +3 more
openalex   +1 more source

Influence of lifestyle factors on susceptibility, disease course and recovery from post COVID-19 syndrome: a scoping review. [PDF]

BMJ Public Health
Blom WM, Dessing MC, Wopereis S, van Bilsen JHM.   +3 more
europepmc   +1 more source

Update on Non‐Biological and RNA‐Based Therapeutics in Chronic Inflammatory Diseases: Precision Medicine Through Small Molecules: An EAACI Position Paper

Allergy, EarlyView.
ABSTRACT In the last decades, critical advancements in research technology and knowledge on disease mechanisms steered therapeutic approaches for chronic inflammatory diseases towards unprecedented target specificity. For allergic and chronic lung diseases, biologic drugs pioneered this goal, acquiring on the way—through the clinical use of monoclonal ...
F. Roth‐Walter, I. M. Adcock, C. Benito‐Villalvilla, R. Bianchini, L. Bjermer, G. Caramori, L. Cari, K. F. Chung, Z. Diamant, I. Eguiluz‐Gracia, E. F. Knol, M. Jesenak, F. Levi‐Schaffer, G. Nocentini, L. O'Mahony, O. Palomares, F. Redegeld, M. Sokolowska, B. Van Esch, M. Zurlo, C. Stellato   +20 more
wiley   +1 more source

Correction: Evidence for a severe cognitive subgroup in a comprehensive neuropsychological Post-COVID-19 syndrome classification. [PDF]

Sci Rep
Balz LT, Erhart DK, Uttner I, Lulé DE, Tumani H.   +4 more
europepmc   +1 more source